India is home to over 100 million people with diabetes and approximately 250 million classified as obese or overweight.[15] What makes the situation uniquely dangerous is the Thin-Fat Indian paradox: South Asians tend to accumulate more visceral (belly) fat, liver fat, and less lean muscle mass at lower body weights than Western populations.[8][9][10] While GLP-1 medications are a global phenomenon, they are particularly critical for the Thin-Fat Indian phenotype
Made possible by a $38 million gift from the Michael & Susan Dell Foundation to the University of Texas at Austin, the DPRI provides research, laboratory, and office space that facilitates interdisciplinary collaboration between academic research, medical research, and clinical initiatives supporting the health and welfare of children
Irene's note: "I've worked with clients who've been on semaglutide and lost twenty kilos, then stopped the medication and gained most of it back within a year
Both IV Push and IV Drip treatments allow for 90-100% vitamin absorption
Some people notice a change within days, while for others it fades more gradually over weeks
GLP-1 stands for Glucagon-Like Peptide-1, a naturally occurring incretin hormone produced in the small intestine that regulates blood glucose levels and appetite